Dose Dependency of the Pharmacokinetics and Acute Lipolytic Actions of Growth Hormone
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The sensitivity to GH is subject to substantial interindividual variations, which has been attributed to differences in age, sex, and body composition. We investigated 18 healthy nonobese men (aged 24-56 yr) on four occasions. The pharmacokinetics and acute lipolytic effects of GH were evaluated using iv bolus injections of either placebo or GH (1, 3, and 6 micro g/kg(-1)). Body composition was determined by computed tomography and bioimpedance measurements, and the lipolytic response was assessed through measurements of circulating lipid intermediates and adipose tissue microdialysis. The metabolic clearance rate was dose dependently reduced with increasing GH doses (57.2 +/- 5.1, 45.2 +/- 3.8, and 39.2 +/- 2.4 ml/min(-1) per meter(-2) following injection of 1, 3, and 6 micro g/kg(-1) GH, respectively, P < 0.001), and half-time was increased (14.2 +/- 0.6, 16.2 +/- 0.4, and 18.0 +/- 0.5 min, respectively, P < 0.0001). The pharmacokinetic variables were not correlated to age or body composition at any GH dose, but GH-binding protein was the major predictor of metabolic clearance rate following the two highest GH doses as indicated by multivariate regression analysis (r(2) = 0.55, P < 0.001 and r(2) = 0.35, P = 0.012, respectively). There was a significant dose-response relationship between injected GH and the subsequent increments in lipid intermediates, but the integrated lipolytic response was not correlated to GH pharmacokinetics, age, or body composition at any GH dose. Taken together, our findings suggest that differences in GH-binding protein concentrations, which possibly reflect GHR expression, determine GH pharmacokinetics rather than age or body composition per se.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IRANMANESH, A., LIZARRALDE, G., & VELDHUIS, J. D. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1081 · Cited by 672
Cited by
Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects
Møller, N., & Jørgensen, J. O. L. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0027 · Cited by 1,039
Self-citationDissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease
Nielsen, T. S., Jessen, N., Jørgensen, J. O. L., Møller, N., & Lund, S. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0277 · Cited by 380
Self-citationSystemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Gadelha, M. R., Kasuki, L., Lim, D. S. T., & Fleseriu, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00115 · Cited by 363
Hormone Replacement Therapy and Physical Function in Healthy Older Men. Time to Talk Hormones?
Giannoulis, M. G., Martin, F. C., Nair, K. S., Umpleby, A. M., & Sonksen, P. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1002 · Cited by 132
Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans
Djurhuus, C. B., Gravholt, C. H., Nielsen, S., Pedersen, S. B., Møller, N., & Schmitz, O. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00199.2003 · Cited by 131
“Insulin, pmol/l Baseline 37[19;82] 34[13;69] 36[29;91] 30[16;82] Stimulated 33[21;69] 33[27;71] 38[30;75] 31[24;70] C-peptide, pmol/l Baseline 332[56;1,042] 223[20;592] 417[98;1,082] 231[72;671] Stimulated 56[0;342] 10[0;97] 60[0;350]* 50[0;157] Glucagon, ng/l Baseline 16[4;78] 22[6;88] 18[4;64] 20[1;88] Stimulated 18…”
Self-citation
Metadata
- Authors
- Hansen, T. K., Gravholt, C. H., Ørskov, H., Rasmussen, M. H., Christiansen, J. S., & Jørgensen, J. O. L.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-10
- Volume
- 87
- Issue
- 10
- Pages
- 4691-4698
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1979103441
- Cited by
- 60
- References
- 1
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.